Checkpoint Therapeutics Inc. (CKPT) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Comparison side by side

Both Checkpoint Therapeutics Inc. (NASDAQ:CKPT) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Checkpoint Therapeutics Inc. 1 0.00 27.15M -0.85 0.00
Rocket Pharmaceuticals Inc. 22 -1.36 29.10M -1.85 0.00

Table 1 demonstrates Checkpoint Therapeutics Inc. and Rocket Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us Checkpoint Therapeutics Inc. and Rocket Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Checkpoint Therapeutics Inc. 1,920,628,183.36% -340% -158.3%
Rocket Pharmaceuticals Inc. 132,816,065.72% -39.8% -30.8%

Liquidity

The Current Ratio of Checkpoint Therapeutics Inc. is 1.8 while its Quick Ratio stands at 1.8. The Current Ratio of rival Rocket Pharmaceuticals Inc. is 11.1 and its Quick Ratio is has 11.1. Rocket Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Checkpoint Therapeutics Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Checkpoint Therapeutics Inc. and Rocket Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Checkpoint Therapeutics Inc. 0 0 0 0.00
Rocket Pharmaceuticals Inc. 0 0 3 3.00

On the other hand, Rocket Pharmaceuticals Inc.’s potential upside is 76.03% and its average target price is $37.67.

Institutional and Insider Ownership

Institutional investors held 12.4% of Checkpoint Therapeutics Inc. shares and 96.9% of Rocket Pharmaceuticals Inc. shares. 1.3% are Checkpoint Therapeutics Inc.’s share held by insiders. Insiders Competitively, held 5.12% of Rocket Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Checkpoint Therapeutics Inc. -4.55% -33.33% -53.51% -72.79% -44.49% -30.77%
Rocket Pharmaceuticals Inc. 27.15% 50.61% 80.22% 35.55% 48.01% 50.91%

For the past year Checkpoint Therapeutics Inc. had bearish trend while Rocket Pharmaceuticals Inc. had bullish trend.

Summary

On 7 of the 11 factors Rocket Pharmaceuticals Inc. beats Checkpoint Therapeutics Inc.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.